top of page

Janssen submits EU application for rheumatoid arthritis drug

Janssen has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) seeking approval of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), a chronic, systemic inflammatory condition that affects approximately 6.2 million Europeans.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page